Effect of Oral Nintedanib vs Placebo on Epistaxis in Hereditary Hemorrhagic Telangiectasia
Study Overview
Epistaxis, or nosebleeds, significantly impacts patients with hereditary hemorrhagic telangiectasia (HHT). Nintedanib, known for its ability to inhibit blood vessel growth, was tested for its effectiveness in reducing the duration of these nosebleeds.
Trial Details
This study was a multicenter, phase 2 trial conducted from June 2020 to February 2023. It involved:
- Participants aged 18 and older with a confirmed HHT diagnosis.
- Patients experiencing moderate to severe nosebleeds (epistaxis severity score > 4).
Results
Sixty patients were randomly assigned to receive either nintedanib or a placebo for 12 weeks, followed by an additional 12 weeks of monitoring. Key findings include:
- 56 patients completed the trial.
- 43% of the nintedanib group achieved a significant reduction in nosebleed duration compared to 27% in the placebo group.
- Median epistaxis duration decreased by 57% in the nintedanib group versus 27% in the placebo group.
- Hemoglobin levels increased significantly in the nintedanib group (+18 g/L) compared to a decrease in the placebo group (-1 g/L).
Conclusion
While the primary goal of reducing epistaxis duration by 50% was not met, the results indicate that nintedanib can significantly reduce the duration of nosebleeds and improve hemoglobin levels in HHT patients. Further research is necessary to confirm these findings.
Clinical Implications
Clinical trials are essential for developing effective treatments. To enhance patient care, our AI-driven platform, DocSym, consolidates clinical standards and research into an accessible resource for healthcare providers.
Streamlining Healthcare
In today’s fast-paced medical environment, efficiency is vital. Our mobile apps facilitate:
- Scheduling and monitoring treatments.
- Telemedicine services for better patient management.
Improving Patient Outcomes
By leveraging AI, clinics can optimize workflows, enhance patient outcomes, and reduce reliance on paper processes. Discover how we can assist you at aidevmd.com.
